Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders
October 19, 2023 11:45 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special...
Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders
October 11, 2023 11:45 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the...
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
August 19, 2022 09:29 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference
November 29, 2021 09:15 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio to Present at the H.C. Wainwright 23rd Annual Global Conference
September 09, 2021 08:00 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Vyant Bio to Present at A.G.P.’s Virtual MedTech Summer Conference
July 27, 2021 08:30 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery, is pleased to announce that Jay Roberts,...
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
May 17, 2021 17:15 ET
|
Vyant Bio, Inc.
Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other...
Vyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021
May 13, 2021 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is focused on integrating human-powered scientific and technology-based systems to...
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
April 22, 2021 08:00 ET
|
Vyant Bio, Inc.
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Vyant Bio Announces Newly Appointed Board of Directors
April 05, 2021 16:20 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and...